News + Resources
Keep up with the latest
Featured
Recent
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
This Scientist Is Building Custom Gene-Editing Tools
November 11, 2024
This Scientist Is Building Custom Gene-Editing Tools
November 11, 2024
Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024
October 30, 2024
Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024
October 30, 2024
All Stories
News
A CRISPR collaboration compilation
February 19, 2024
Nature
Read Now
Press
A CRISPR collaboration compilation
February 19, 2024
Nature
Read Now
News
Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target
February 7, 2024
Citeline Scrip
Read Now
Press
Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target
February 7, 2024
Citeline Scrip
Read Now
News
A road to survival
January 17, 2024
ASBMB Today
Read Now
Press
A road to survival
January 17, 2024
ASBMB Today
Read Now
News
Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target
January 3, 2024
Read Now
Press
Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target
January 3, 2024
Read Now